Tag: OCRI
Abemaciclib + Endocrine Therapy Improves Survival in HR-Positive, HER2-Negative Early Breast Cancer
15.8 percent lower risk for death seen with abemaciclib-ET versus ET in intent-to-treat population
Nearly Half With Early-Stage Breast Cancer Extend Endocrine Therapy Beyond Five Years
Decision-making was influenced by patient values and did not vary by stage, race and ethnicity, or demographics
ASCO: Elinzanetant Cuts Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy
Findings seen in women with moderate-to-severe vasomotor symptoms associated with endocrine therapy for HR-positive breast cancer
